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Background
In healthy volunteers, we sought to determine the safety,
tolerability, and immunogenicity of ADVAX, a subtype B'/
C, DNA-based, multigenic, HIV-1 vaccine candidate,
when injected intramuscularly immediately followed by
in vivo electroporation (EP) using the TriGrid™ Delivery
System.
Methods
Forty healthy volunteers aged 18–60 were enrolled in a
double blind randomized phase-I trial. Eight volunteers
each received either low dose (LD, 0.2 mg); mid dose
(MD, 1.0 mg); or high dose (HD, 4.0 mg) ADVAX or
saline placebo via EP. Another eight volunteers received
4.0 mg ADVAX intramuscularly (IM). Vaccinations were
given at weeks 0 and 8. The protocol was subsequently
amended to administer a third dose of HD EP/placebo at
week 36 to volunteers receiving either HD ADVAX via EP
(n = 8) or placebo via EP (n = 3). Total study follow-up is
14 months.
Results
There have been no vaccine or device related serious
adverse events to date. After two vaccinations in all sub-
jects, the IFNg ELISPOT response rates were IM: 1/8
(13%), LD-EP: 3/8 (38%) MD-EP: 7/8 (88%) and HD-EP:
6/8 (75%). In the same order, the mean (range) response
to peptide pools spanning all antigens was 72, 120 (70–
193), 151 (53–440), and 141 (59–336) SFC/million
PBMCs. The breadth of the response improved with EP
and increasing dosage, with responses to 1, 1, 3, and 4 of
the 4 ADVAX gene products. ICCS analysis of ELISPOT
responders revealed a balanced CD4+/CD8+ response.
There were no responses to placebo, by definition. An
analysis of responses after the third vaccination in the
high dosage group is ongoing.
Conclusion
This study is the first demonstration in healthy volunteers
that EP in vivo is safe, tolerable, and effective in improving
the magnitude and breadth of cellular immune responses
to a DNA-based vaccine.
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